Keywords: cv, thera, identifies, diabetes, potential, ranexa, california

CV Thera identifies diabetes potential for Ranexa

Article | 16 July 2007

California, USA-based CV Therapeutics says that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Ranexa

Ranolazine

Humulin 70-30

Insulin

Humulin N

Go to drug listing